Target Price | €26.26 |
Price | €21.01 |
Potential | 25.00% |
Number of Estimates | 19 |
19 Analysts have issued a price target Bayer 2026 . The average Bayer target price is €26.26. This is 25.00% higher than the current stock price. The highest price target is €37.00 76.11% , the lowest is €22.00 4.71% . | |
A rating was issued by 21 analysts: 5 Analysts recommend Bayer to buy, 16 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Bayer stock has an average upside potential 2026 of 25.00% . Most analysts recommend the Bayer stock at Hold. |
17 Analysts have issued a sales forecast Bayer 2024 . The average Bayer sales estimate is €46.4b . This is 0.78% lower than the revenue of the last 12 months(TTM). The highest sales forecast is €47.5b 1.73% , the lowest is €45.8b 2.12% .
This results in the following potential growth metrics:
2023 | €47.6b | 6.11% |
---|---|---|
2024 | €46.4b | 2.65% |
2025 | €46.5b | 0.27% |
2026 | €47.4b | 1.85% |
2027 | €48.0b | 1.36% |
2028 | €49.0b | 2.02% |
17 Analysts have issued an Bayer EBITDA forecast 2024. The average Bayer EBITDA estimate is €10.1b . This is 9.17% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €10.5b 5.62% , the lowest is €9.9b 10.50% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | €12.3b | 1.26% |
---|---|---|
2024 | €10.1b | 18.23% |
2025 | €9.6b | 4.58% |
2026 | €10.1b | 4.87% |
2027 | €10.2b | 1.02% |
2028 | €10.4b | 2.25% |
2023 | 25.91% | 7.86% |
---|---|---|
2024 | 21.76% | 16.01% |
2025 | 20.71% | 4.83% |
2026 | 21.32% | 2.95% |
2027 | 21.25% | 0.33% |
2028 | 21.30% | 0.24% |
7 Bayer Analysts have issued a net profit forecast 2024. The average Bayer net profit estimate is €1.6b . This is 276.85% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €3.6b 512.22% , the lowest is €-147m 83.33% .
This results in the following potential growth metrics and future Net Margins:
2023 | €-2.9b | 170.85% |
---|---|---|
2024 | €1.6b | 153.23% |
2025 | €2.3b | 49.27% |
2026 | €2.8b | 19.85% |
2027 | €3.4b | 20.47% |
2028 | €3.8b | 12.23% |
2023 | -6.17% | 175.47% |
---|---|---|
2024 | 3.37% | 154.65% |
2025 | 5.02% | 48.96% |
2026 | 5.91% | 17.73% |
2027 | 7.02% | 18.78% |
2028 | 7.72% | 9.97% |
7 Analysts have issued a Bayer forecast for earnings per share. The average Bayer <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is €1.59 . This is 276.67% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is €3.71 512.22% , the lowest is €-0.15 83.33% .
This results in the following potential growth metrics and future valuations:
2023 | €-2.99 | 170.85% |
---|---|---|
2024 | €1.59 | 153.18% |
2025 | €2.38 | 49.69% |
2026 | €2.85 | 19.75% |
2027 | €3.43 | 20.35% |
2028 | €3.85 | 12.24% |
Current | -24.16 | 178.98% |
---|---|---|
2024 | 13.60 | 156.29% |
2025 | 9.11 | 33.01% |
2026 | 7.60 | 16.58% |
2027 | 6.31 | 16.97% |
2028 | 5.62 | 10.94% |
Based on analysts' sales estimates for 2024, the Bayer stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 1.25 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 0.46 .
This results in the following potential growth metrics and future valuations:
Current | 1.24 | 18.42% |
---|---|---|
2024 | 1.25 | 0.75% |
2025 | 1.25 | 0.26% |
2026 | 1.22 | 1.81% |
2027 | 1.21 | 1.34% |
2028 | 1.18 | 1.97% |
Current | 0.45 | 31.54% |
---|---|---|
2024 | 0.46 | 0.77% |
2025 | 0.46 | 0.26% |
2026 | 0.45 | 1.82% |
2027 | 0.44 | 1.34% |
2028 | 0.43 | 1.99% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.